Bucillamine is an antirheumatic agent developed from tiopronin. It is mainly used in Japan and Korea. Activity is mediated by the two thiol groups that the molecule contains. Research done in USA showed positive transplant preservation properties. References: Matsuno H, Okada M, Sakai Y, Abe C, Katayama K, Sagawa A, Yamasaki K, Kondo M, Funahashi K, Matsubara T. The Usefulness of a New Triple Combination Treatment Utilizing methotrexate, salazosulfapyridine, and bucillamine in Rheumatoid Arthritis. Mod Rheumatol. 2015 Jun 8:1-20. [Epub ahead of print] PubMed PMID: 26052803.

纯度：≥98%

CAS：65002-17-7